Bladder Cancer
1,087
185
262
472
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
164 trials with published results (15%)
Research Maturity
472 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.7%
105 terminated out of 1087 trials
81.8%
-4.7% vs benchmark
10%
108 trials in Phase 3/4
35%
164 of 472 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 472 completed trials
Clinical Trials (1087)
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Prehabilitation in High-risk Oncologic Surgery
Evaluation for NCI Surgery Branch Clinical Research Protocols
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Quality of Life in Patients With Bladder Cancer